← Human Trials & Peer-Reviewed Studies
Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis, albuminuria, and micro-inflammation in type 2 diabetic patients with insulin treatment: a randomized control trial
Plain-language guide to PMID 27916783 (2017): open-label randomized controlled trial study of Liraglutide in 2 patients.
Key Facts
- PMID
- 27916783
- Journal
- Endocrine journal
- Year
- 2017
- Study type
- Randomized Controlled Trial
- Authors
- Bouchi R et al. (10 authors)
- DOI
- 10.1507/endocrj.EJ16-0449
- Registered trial
- NCT03590626
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Liraglutide, published as a randomized controlled trial.
Participants were randomly assigned to liraglutide plus insulin (liraglutide group) and insulin treatment (control group) at 1:1 allocation.
Primary endpoint was the change in viscera fat are (VFA, cm2) at 24 weeks.
Who Took Part
The study group was 2 patients.
The age groups tagged for this paper are middle-aged adults, both men and women.
Type 2 diabetic patients with insulin treatment were enrolled in this randomized, open-label, comparative study.
How the Study Was Run
The researchers set it up as a randomized, open-label and parallel-group study.
Random assignment meant chance, not the researchers, decided who got Liraglutide and who got the comparison, which limits bias.
Being open-label, the Liraglutide study did not mask who received what.
The Liraglutide group and the comparison group ran side by side rather than switching.
What Was Measured
Primary endpoint was the change in viscera fat are (VFA, cm2) at 24 weeks.
Liver attenuation index (LAI) measured by abdominal computed tomography, urinary albumin-to-creatinine ratio (ACR, mg/g), and C-reactive protein (CRP) levels, skeletal muscle index (SMI), and quality of life (QOL) related to diabetes treatment were also determined.
Topics PubMed links to this paper include Adiposity, Albuminuria, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Diabetic Cardiomyopathies and Diabetic Nephropathies.
What This Means in Plain Language
The paper is a randomized, open-label and parallel-group study of Liraglutide in 2 patients.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 2017 (Endocrine journal), a journal based in Japan.
More context: the Liraglutide compound page.
Our Notes on the Compound
Liraglutide: A once-daily GLP-1 receptor agonist peptide; sold as Victoza for type 2 diabetes and Saxenda for weight management.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.